Company Overview and News

Corazon Mining advances core projects against backdrop of strong commodity prices

Corazon Mining Ltd (ASX:CZN) managing director Brett Smith speaks to Proactive Investors about the company's two core projects, namely the Lynn Lake Nickel-Cobalt Project in Canada and the Mount Gilmore Cobalt-Copper-Gold Project in Australia.

Cobalt Miners News For The Month Of April 2018

2018-04-25 seekingalpha
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.

Castillo Copper adds cobalt targets at Cangai Project

Castillo Copper Ltd (ASX:CCZ) has identified new primary cobalt targets at surface within the Cangai Project in New South Wales which previously focused on copper.

A Look At The Junior Cobalt Miners In Early 2018

2018-04-17 seekingalpha
This article first appeared on Trend Investing on February 16, therefore all data is as of that date.

Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.

Corazon Mining discovers four new cobalt-copper-gold anomalies

Corazon Mining Ltd (ASX:CZN) has identified four new cobalt-copper-gold anomalies through soil sampling at its Cobalt Ridge prospect within the Mt Gilmore Project, New South Wales.

Corazon Mining intersects widespread sulphide mineralisation at Lynn Lake

Corazon Mining Ltd (ASX:CZN) has observed disseminated sulphide mineralisation in recent diamond drilling completed at its Lynn Lake Project in Canada.

Cobalt Miners News For The Month Of February 2018

2018-02-23 seekingalpha
Cobalt market news - the DRC to hike taxes on Congo cobalt miners. ERG says "cobalt boom ‘guaranteed’ for 7-10 years."

Corazon Mining commences drilling targeting nickel-copper-cobalt

Corazon Mining Ltd (ASX:CZN) has commenced drilling at the Fraser Lake Complex within the Lynn Lake Project in Canada.

Corazon Mining gets ready to drill for nickel-copper-cobalt in Canada

Corazon Mining Ltd (ASX:CZN) is commencing the next phase of drilling at its Fraser Lake Complex in Canada this month.

Cobalt Miners News For The Month Of January 2018

2018-01-24 seekingalpha
Cobalt spot price news - Cobalt prices up again in January. "BMO Capital Markets expects current cobalt prices to double in the next two years."

Corazon Mining secures $3.4 million for cobalt and nickel assets

Corazon Mining Ltd (ASX:CZN) has received commitments from sophisticated and institutional investors to raise $3.4 million in funding through a share placement.

Corazon Mining calls for halt pending update on capital raise

Corazon Mining Ltd (ASX:CZN) is preparing to outline details in relation to its capital raising, and the ASX has granted the company a trading halt to prepare.

Corazon Mining's Cobalt Ridge drill results prompt management to identify extensions

Corazon Mining Ltd’s (ASX:CZN) final assay results from its 18-hole 3.2 kilometre drilling program at Cobalt Ridge include an intersection of 5 metres at 0.53% cobalt, 0.16% copper and 0.08 g/t gold.

Cobalt Miners News For The Month Of December 2017

2017-12-22 seekingalpha
Cobalt market news - "Electric vehicle revolution a rare investment opportunity as metals demand spikes." "BMW sees 10-fold jump in its need for battery materials by 2025."

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...